THE PRESENT INVENTION PROVIDES AA TARGETING COMPOUNDS WHICH COMPRISE AA TARGETING AGENT-LINKER CONJUGATES WHICH ARE LINKED TO A COMBINING SITE OF AN ANTIBODY. VARIOUS USES OF THE COMPOUNDS ARE PROVIDED, INCLUDING METHODS TO TREAT DISORDERS CONNECTED TO ABNORMAL ANGIOGENESIS.